Cyclopharm Making Solid Progress in Executing its FY19 Strategic Priorities

  • Dec 10, 2019 AEDT
  • Team Kalkine

Cyclopharm Limited (ASX: CYC) provides an update on progressing its strategy during FY19, which includes expectations for its full year results and advancement of certain operational matters, including acquiring United States Food and Drug Administration (USFDA) approval to begin commercial launch of TechnegasTM into the US in 2020.

  • US commercial launch expected in 2020 and the company is building sales support for rapid market entry;
  • The company has received $3.0 million AusIndustry R&D refund from the ATO;
  • FY2019 sales expected to be in line with previous year.

At AEST 01:29PM, the stock was trading at $1.065 per share, no change from its previous close

 

All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK